440 related articles for article (PubMed ID: 16890801)
1. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
4. Novel anticancer drug discovery.
Buolamwini JK
Curr Opin Chem Biol; 1999 Aug; 3(4):500-9. PubMed ID: 10419854
[TBL] [Abstract][Full Text] [Related]
5. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
6. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia.
Michie AM; Nakagawa R
Hematol Oncol; 2006 Sep; 24(3):134-8. PubMed ID: 16841369
[TBL] [Abstract][Full Text] [Related]
7. [Role of PKCbeta in the malignant tumors and enzastaurin, a PKCbeta inhibitor].
Li XY; Chen XG
Yao Xue Xue Bao; 2009 May; 44(5):449-55. PubMed ID: 19618717
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
Wang Y; An R; Dong X; Pan S; Duan G; Sun X
Urol Int; 2009; 82(2):214-21. PubMed ID: 19322013
[TBL] [Abstract][Full Text] [Related]
9. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Herbst RS; Oh Y; Wagle A; Lahn M
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
[TBL] [Abstract][Full Text] [Related]
10. PKC inhibitors: potential in T cell-dependent immune diseases.
Baier G; Wagner J
Curr Opin Cell Biol; 2009 Apr; 21(2):262-7. PubMed ID: 19195860
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
12. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
13. [The signal transduction pathway of multi-target kinase inhibitors as anticancer agents in clinical use or in phase III].
Wu W; Lu C; Chen SY; Yu NF
Yao Xue Xue Bao; 2009 Mar; 44(3):242-57. PubMed ID: 19449520
[TBL] [Abstract][Full Text] [Related]
14. [Novel targets for cancer chemotherapy].
Inoue S
Gan To Kagaku Ryoho; 1996 Jan; 23(2):191-201. PubMed ID: 8611047
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model.
Grant S; Tran P; Zhang Q; Zou A; Dinh D; Jensen J; Zhou S; Kang X; Zachwieja J; Lippincott J; Liu K; Johnson SL; Scales S; Yin C; Nukui S; Stoner C; Prasanna G; Lafontaine J; Wells P; Li H
Eur J Pharmacol; 2010 Feb; 627(1-3):16-25. PubMed ID: 19850035
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
Mikalsen T; Gerits N; Moens U
Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
[TBL] [Abstract][Full Text] [Related]
17. Key cancer cell signal transduction pathways as therapeutic targets.
Bianco R; Melisi D; Ciardiello F; Tortora G
Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
[TBL] [Abstract][Full Text] [Related]
18. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
Brachmann S; Fritsch C; Maira SM; García-Echeverría C
Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]